Matthew S Shotwell1, Ross Nesbitt2, Phillip N Madonia2, Edward R Gould2, Michael J Connor3, Charbel Salem4, Olufemi A Aduroja5, Milen Amde6, Joseph J Groszek2, Peilin Wei1, Maria E Taylor7, Ashita J Tolwani7, William H Fissell8. 1. Departments of Biostatistics. 2. Nephrology and Hypertension, and. 3. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, Georgia; 4. Department of Nephrology and Hypertension, King's Daughters Medical Center, Ashland, Kentucky; 5. Department of Internal Medicine, Marion General Hospital, Marion, Ohio; 6. Department of Internal Medicine and Nephrology, Veterans Affairs Southern Nevada Healthcare System, Las Vegas, Nevada; and. 7. Department of Nephrology and Hypertension, University of Alabama at Birmingham, Birmingham, Alabama. 8. Nephrology, Hypertension, and Biomedical Engineering, Vanderbilt University, Nashville, Tennessee; william.fissell@vanderbilt.edu.
Abstract
BACKGROUND AND OBJECTIVES: Infection is the most common cause of death in severe AKI, but many patients receiving continuous RRT do not reach target antibiotic concentrations in plasma. Extended infusion of β-lactams is associated with improved target attainment in critically ill patients; thus, we hypothesized that extended infusion piperacillin-tazobactam would improve piperacillin target attainment compared with short infusion in patients receiving continuous RRT. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an institutional review board-approved observational cohort study of piperacillin-tazobactam pharmacokinetics and pharmacodynamics in critically ill patients receiving continuous venovenous hemodialysis and hemodiafiltration at three tertiary care hospitals between 2007 and 2015. Antibiotic concentrations in blood and/or dialysate samples were measured by liquid chromatography, and one- and two-compartment pharmacokinetic models were fitted to the data using nonlinear mixed effects regression. Target attainment for piperacillin was defined as achieving four times the minimum inhibitory concentration of 16 μg/ml for >50% of the dosing cycle. The probabilities of target attainment for a range of doses, frequencies, and infusion durations were estimated using a Monte Carlo simulation method. Target attainment was also examined as a function of patient weight and continuous RRT effluent rate. RESULTS: Sixty-eight participants had data for analysis. Regardless of infusion duration, 6 g/d piperacillin was associated with ≤45% target attainment, whereas 12 g/d was associated with ≥95% target attainment. For 8 and 9 g/d, target attainment ranged between 68% and 85%. The probability of target attainment was lower at higher effluent rates and patient weights. For all doses, frequencies, patient weights, and continuous RRT effluent rates, extended infusion was associated with higher probability of target attainment compared with short infusion. CONCLUSIONS: Extended infusions of piperacillin-tazobactam are associated with greater probability of target attainment in patients receiving continuous RRT.
BACKGROUND AND OBJECTIVES: Infection is the most common cause of death in severe AKI, but many patients receiving continuous RRT do not reach target antibiotic concentrations in plasma. Extended infusion of β-lactams is associated with improved target attainment in critically illpatients; thus, we hypothesized that extended infusion piperacillin-tazobactam would improve piperacillin target attainment compared with short infusion in patients receiving continuous RRT. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an institutional review board-approved observational cohort study of piperacillin-tazobactam pharmacokinetics and pharmacodynamics in critically illpatients receiving continuous venovenous hemodialysis and hemodiafiltration at three tertiary care hospitals between 2007 and 2015. Antibiotic concentrations in blood and/or dialysate samples were measured by liquid chromatography, and one- and two-compartment pharmacokinetic models were fitted to the data using nonlinear mixed effects regression. Target attainment for piperacillin was defined as achieving four times the minimum inhibitory concentration of 16 μg/ml for >50% of the dosing cycle. The probabilities of target attainment for a range of doses, frequencies, and infusion durations were estimated using a Monte Carlo simulation method. Target attainment was also examined as a function of patient weight and continuous RRT effluent rate. RESULTS: Sixty-eight participants had data for analysis. Regardless of infusion duration, 6 g/d piperacillin was associated with ≤45% target attainment, whereas 12 g/d was associated with ≥95% target attainment. For 8 and 9 g/d, target attainment ranged between 68% and 85%. The probability of target attainment was lower at higher effluent rates and patient weights. For all doses, frequencies, patient weights, and continuous RRT effluent rates, extended infusion was associated with higher probability of target attainment compared with short infusion. CONCLUSIONS: Extended infusions of piperacillin-tazobactam are associated with greater probability of target attainment in patients receiving continuous RRT.
Authors: Seth R Bauer; Charbel Salem; Michael J Connor; Joseph Groszek; Maria E Taylor; Peilin Wei; Ashita J Tolwani; William H Fissell Journal: Clin J Am Soc Nephrol Date: 2012-01-26 Impact factor: 8.237
Authors: Brian VanScoy; Rodrigo E Mendes; Anthony M Nicasio; Mariana Castanheira; Catharine C Bulik; Olanrewaju O Okusanya; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose Journal: Antimicrob Agents Chemother Date: 2013-04-29 Impact factor: 5.191
Authors: Glenn M Chertow; Elisabeth Burdick; Melissa Honour; Joseph V Bonventre; David W Bates Journal: J Am Soc Nephrol Date: 2005-09-21 Impact factor: 10.121
Authors: Gary R Matzke; George R Aronoff; Arthur J Atkinson; William M Bennett; Brian S Decker; Kai-Uwe Eckardt; Thomas Golper; Darren W Grabe; Bertram Kasiske; Frieder Keller; Jan T Kielstein; Ravindra Mehta; Bruce A Mueller; Deborah A Pasko; Franz Schaefer; Domenic A Sica; Lesley A Inker; Jason G Umans; Patrick Murray Journal: Kidney Int Date: 2011-09-14 Impact factor: 10.612
Authors: Michael J Connor; Charbel Salem; Seth R Bauer; Christina L Hofmann; Joseph Groszek; Robert Butler; Susan J Rehm; William H Fissell Journal: Antimicrob Agents Chemother Date: 2010-11-29 Impact factor: 5.191
Authors: Janattul-Ain Jamal; Darren M Roberts; Andrew A Udy; Mohd-Basri Mat-Nor; Fariz-Safhan Mohamad-Nor; Steven C Wallis; Jeffrey Lipman; Jason A Roberts Journal: Int J Antimicrob Agents Date: 2015-03-28 Impact factor: 5.283
Authors: Raymond K Hsu; Charles E McCulloch; R Adams Dudley; Lowell J Lo; Chi-yuan Hsu Journal: J Am Soc Nephrol Date: 2012-12-06 Impact factor: 10.121
Authors: Paul M Palevsky; Jane Hongyuan Zhang; Theresa Z O'Connor; Glenn M Chertow; Susan T Crowley; Devasmita Choudhury; Kevin Finkel; John A Kellum; Emil Paganini; Roland M H Schein; Mark W Smith; Kathleen M Swanson; B Taylor Thompson; Anitha Vijayan; Suzanne Watnick; Robert A Star; Peter Peduzzi Journal: N Engl J Med Date: 2008-05-20 Impact factor: 91.245
Authors: David Afshartous; Seth R Bauer; Michael J Connor; Olufemi A Aduroja; Milen Amde; Charbel Salem; Joseph J Groszek; William H Fissell Journal: Am J Kidney Dis Date: 2013-10-19 Impact factor: 8.860
Authors: Faeq Husain-Syed; Zaccaria Ricci; Daniel Brodie; Jean-Louis Vincent; V Marco Ranieri; Arthur S Slutsky; Fabio Silvio Taccone; Luciano Gattinoni; Claudio Ronco Journal: Intensive Care Med Date: 2018-07-24 Impact factor: 17.440
Authors: Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson Journal: Ann Intensive Care Date: 2017-11-10 Impact factor: 6.925
Authors: Daniel J Selig; Jesse P DeLuca; Kevin K Chung; Kaitlin A Pruskowski; Jeffrey R Livezey; Robert J Nadeau; Elaine D Por; Kevin S Akers Journal: J Clin Pharm Ther Date: 2022-03-29 Impact factor: 2.145